Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 395

1.

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.

Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.

JAMA. 1993 Dec 1;270(21):2590-7.

PMID:
8230644
2.

Drug-induced torsade de pointes.

Raehl CL, Patel AK, LeRoy M.

Clin Pharm. 1985 Nov-Dec;4(6):675-90. Review.

PMID:
2416504
3.

Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.

Kühlkamp V, Mermi J, Mewis C, Seipel L.

J Cardiovasc Pharmacol. 1997 Mar;29(3):373-81.

PMID:
9125676
4.

Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.

Faber TS, Zehender M, Van de Loo A, Hohnloser S, Just H.

Clin Cardiol. 1994 Apr;17(4):197-202.

5.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Skanes AC, Morton BC, Green MS, Tang AS.

Can J Cardiol. 1997 Apr;13(4):383-6. Review.

PMID:
9141970
6.
8.
9.

Experimental models of torsades de pointes.

Weissenburger J, Davy JM, Chézalviel F.

Fundam Clin Pharmacol. 1993;7(1):29-38. Review.

PMID:
8458600
10.

Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.

Couderc JP, Kaab S, Hinterseer M, McNitt S, Xia X, Fossa A, Beckmann BM, Polonsky S, Zareba W.

J Clin Pharmacol. 2009 Jan;49(1):6-16. doi: 10.1177/0091270008325927. Epub 2008 Oct 28.

PMID:
18957528
11.

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.

Hohnloser SH, Klingenheben T, Singh BN.

Ann Intern Med. 1994 Oct 1;121(7):529-35. Review.

PMID:
8067651
12.
13.

Antiarrhythmic drugs and torsade de pointes.

Lazzara R.

Eur Heart J. 1993 Nov;14 Suppl H:88-92. Review.

PMID:
8293758
14.

Torsades de pointes, a common arrhythmia, induced by medication.

Ko PT, Gulamhusein S, Kostuk WJ, Klein GJ.

Can Med Assoc J. 1982 Sep 1;127(5):368-72.

15.

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.

Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.

Circulation. 1992 Nov;86(5):1376-82.

PMID:
1423949
16.

[Sotalol and torsades de pointes ventricular tachycardia].

Petersen HH, Sandøe E.

Ugeskr Laeger. 1996 May 6;158(19):2711-6. Danish.

PMID:
8744073
17.

Cardiovascular drugs inducing QT prolongation: facts and evidence.

Taira CA, Opezzo JA, Mayer MA, Höcht C.

Curr Drug Saf. 2010 Jan;5(1):65-72. Review.

PMID:
20210721
18.

Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.

Wolbrette DL.

Am J Cardiol. 2003 Mar 20;91(6A):39D-44D. Review.

PMID:
12670641
19.

A case series of drug-induced long QT syndrome and Torsade de Pointes.

Tong KL, Lau YS, Teo WS.

Singapore Med J. 2001 Dec;42(12):566-70.

PMID:
11989578
20.

JTc prolongation with d,l-sotalol in women versus men.

Lehmann MH, Hardy S, Archibald D, MacNeil DJ.

Am J Cardiol. 1999 Feb 1;83(3):354-9.

PMID:
10072223

Supplemental Content

Support Center